What Is Veozah and How It Targets Hot Flashes
Veozah (fezolinetant) is an oral neurokinin 3 receptor antagonist approved by the U.S. Food and Drug Administration for the treatment of moderate-to-severe vasomotor symptoms due to menopause, including hot flashes and night sweats, when hormonal therapy is not recommended. The approval was based on randomized clinical trials showing statistically significant reductions in daily hot flash frequency and severity compared with placebo, with the most pronounced effect seen in the first four to eight weeks of treatment. Veozah works by blocking NK3 receptors in the hypothalamus, which helps stabilize the body's temperature regulation without using estrogen or progestin, making it a non-hormonal option for women who cannot or prefer not to use hormone therapy. For more on the regulatory pathway and trial design, see the FDA label information on the FDA website.
In pivotal Phase 3 trials, women taking Veozah experienced a mean reduction of approximately 5 to 7 moderate-to-severe hot flashes per day compared with baseline, with responder rates showing over 50 percent of patients achieving at least a 50 percent reduction in daily hot flash frequency by week 12. Common side effects include abdominal pain, diarrhea, insomnia, and elevated liver enzymes, which is why the prescribing information includes a recommendation to monitor liver function tests at baseline and during treatment. The drug is taken as a 45 mg tablet once daily, and it is indicated for postmenopausal women with an intact uterus, with no requirement for additional progestin therapy. Veozah's mechanism is distinct from gabapentinoids and selective serotonin reuptake inhibitors, offering a targeted approach to the neurokinin system involved in thermoregulation.
Veozah Market Position, Pricing, and Commercial Trajectory
Veozah is marketed in the United States by Astellas Pharma, which launched the product following FDA approval and has focused on positioning it as a differentiated non-hormonal therapy in a market where estrogen-based treatments remain common but carry contraindications for many women. The product is available by prescription only, and coverage varies across commercial insurance plans, Medicare Part D, and Medicaid, with manufacturer copay assistance programs in place to reduce out-of-pocket costs for eligible patients. Real-world adoption data from the first full quarters after launch show steady growth in prescriptions, supported by direct-to-consumer advertising and medical education initiatives targeting obstetricians, gynecologists, and primary care providers. For broader context on the menopause therapeutics market and competitive landscape, see industry analysis from Forbes covering biotech and women's health trends.
In head-to-head comparisons with existing non-hormonal options such as low-dose paroxetine mesylate, Veozah has demonstrated comparable or superior efficacy on hot flash frequency with a different side-effect profile that avoids serotonergic effects. The pricing strategy positions Veozah at a premium relative to generic alternatives, but payers have generally included it on formularies with step-therapy requirements or prior authorization, reflecting its novel mechanism and targeted indication. Astellas has reported commercial revenue figures in quarterly earnings releases, with analysts noting that Veozah sales have contributed to growth in the company's neuroscience portfolio. Market research reports indicate that the global menopause therapeutics market is expanding, with non-hormonal therapies expected to capture a growing share as awareness increases and treatment guidelines evolve to include non-hormonal options as first-line therapy for many patients.
Veozah Safety Profile, Access, and Ongoing Research
The Veozah prescribing information includes a boxed warning for hepatotoxicity, based on clinical trial data showing rare instances of serious liver injury, which led to the requirement for periodic liver function monitoring